Wissenschaftliche Arbeiten

Uzm. Dr. Gökçe Melis Çolak

11 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Missed Opportunities for HIV Testing in Hospitalised Adults in Türkiye: Indicator Conditions and Testing Coverage in a National Multicentre Point-Prevalence Survey (HIV-ICs-TR)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-54294-6 PMID 42218185 Frei zugänglicher VolltextQuelle: ORCID

  2. Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry

    American Journal of Hematology, 2025

    DOI 10.1002/ajh.70166 PMID 41439460 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  3. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection, 2024

    DOI 10.1007/s15010-023-02169-7 PMID 38388854 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  4. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, 2024

    DOI 10.1016/j.eclinm.2024.102553 PMID 38533127 38 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  5. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry

    Haematologica, 2024

    DOI 10.3324/haematol.2023.284678 PMID 38572549 11 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  6. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, 2024

    DOI 10.1002/hon.3240 PMID 38050405 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  7. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, 2023

    DOI 10.1016/j.ijid.2023.10.013 PMID 37863310 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  8. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, 2023

    DOI 10.1016/j.ijantimicag.2023.106952 PMID 37582478 12 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  9. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000972964.65137.d1 Frei zugänglicher VolltextQuelle: ORCID

  10. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

    Cancers, 2022

    DOI 10.3390/cancers14225530 PMID 36428621 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  11. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

    HemaSphere, 2022

    DOI 10.1097/hs9.0000000000000789 PMID 36310756 29 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID